INTRODUCTION {#s1}
============

Esophageal cancer is the sixth most common cancer and fourth leading cause of cancer-related death in China \[[@R1]\]. In contrast to Western countries, esophageal squamous cell carcinoma (ESCC) continues to be the predominant subtype in Chinese population, with a high burden of morbidity and mortality \[[@R1]--[@R3]\]. Although great progress has been made in the diagnosis and treatment of ESCC in last decades, the prognosis remains unfavorable, with a 5-year overall survival (OS) rate of less than 40% \[[@R1]\].

The American Joint Committee on Cancer (AJCC), the Union for International Cancer Control (UICC) tumor-node-metastasis (TNM) staging system, and the histopathological findings are the most widely used prognostic factors to stratify survival in ESCC \[[@R4]--[@R6]\]. Besides, some inflammation-based prognostic indexes, such as the Glasgow Prognostic Score (GPS), modified GPS (mGPS), the preoperative plasmatic gamma-glutamyltransferase levels, new data regarding platelet-lymphocyte ratio (PLR), neutrophil-lymphocyte ratio (NLR) and lymphocyte-monocyte ratio (LMR) have also been identified as potential prognostic factors in ESCC \[[@R7]--[@R11]\]. However, more accurate indicators are still desirable for risk classification and optimal management of ESCC patients.

Rather than serving as an indicator of activated hemostatic system and a trigger for increased thromboembolic events, hyperfibrinogenemia is frequently observed in various malignancies, including ESCC, and has been demonstrated to play vital roles in tumor progression, invasion and distant metastasis \[[@R12]--[@R15]\]. In addition, it has also been identified to be significantly associated with advanced clinical stage and unfavorable survival in ESCC patients \[[@R16]--[@R20]\]. Furthermore, systemic inflammation has been reported to be associated with impaired survival in patients with cancer \[[@R21]--[@R22]\]. However, inflammation and C-reactive protein (CRP) levels are not always elevated in esophageal cancer patients \[[@R23]--[@R24]\], leaving CRP insufficient for high-risk stratification. Therefore, we proposed that in combination with fibrinogen, CRP might provide a more accurate prediction formula in predicting long-term survival for resectable ESCC patients.

The purpose of this present study was to assess the relationship between preoperative fibrinogen and CRP (FC) score and clinicopathologic variables, and to investigate its prognostic significance in ESCC patients.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

The baseline clinicopathologic characteristics of the included 260 patients were demonstrated in Table [1](#T1){ref-type="table"}. The median age at diagnosis was 59.0 years (ranged, 20.0-87.0 years). The vast majority (74.2%) of the patients were males. Primary tumors were located at the middle esophagus in 61.5 % of the patients. And the numbers of patients with poorly/not differentiated, moderately differentiated and well differentiated tumors were 58 (22.3%), 135 (51.9%) and 67 (25.8%) respectively. Tumor invasion depth of T1, T2, T3, and T4 were observed in 25 (9.6%), 46 (17.7%), 168 (64.6%), and 21 (8.1%) of the patients, respectively. Lymph node metastasis was negative in 144 (55.0%) of the patients. Of these, 24 (9.2%) were stage I, 127 (48.8%) were stage II and 107 (41.9%) were stage III (Table [1](#T1){ref-type="table"}).

###### Correlation between preoperative FC scores and clinicopathological characteristics in 260 ESCC patients

  Clinicopathologic characteristics   Patients N (%)   FC score (N, %)   *P* value               
  ----------------------------------- ---------------- ----------------- ----------- ----------- ---------------------------------------------
  Age (years)                                                                                    0.962
   \< 60                              150 (57.7)       106 (57.3)        26 (57.8)   18 (60.0)   
   ≥ 60                               110 (42.3)       79 (42.7)         19 (42.2)   12 (40.0)   
  Gender                                                                                         0.224
   Male                               193 (74.2)       133 (71.9)        38 (84.4)   22 (73.3)   
   Female                             67 (25.8)        52 (28.1)         7 (15.6)    8 (26.7)    
  Tumor location                                                                                 0.177
   Upper                              20 (7.7)         14 (7.6)          4 (8.9)     2 (6.7)     
   Middle                             160 (61.5)       120 (64.9)        27 (60.0)   13 (43.3)   
   Lower                              80 (30.8)        51 (27.5)         14 (31.1)   15 (50.0)   
  Tumor length (cm)                                                                              0.055
   \< 5                               149 (57.3)       114 (61.6)        23 (51.1)   12 (40.0)   
   ≥ 5                                111 (42.7)       71 (38.4)         22 (48.9)   18 (60.0)   
  Differentiation                                                                                0.043[\*](#tfn_001){ref-type="table-fn"}
   Well                               67 (25.8)        50 (27.1)         5 (11.1)    12 (40.0)   
   Moderate                           135 (51.9)       92 (49.7)         28 (62.2)   15 (50.0)   
   Poor/Undifferentiated              58 (22.3)        43 (23.2)         12 (26.7)   3 (10.0)    
  T stage                                                                                        0.007[\*](#tfn_001){ref-type="table-fn"}
   T1                                 25 (9.6)         24 (13.0)         0           1 (3.3)     
   T2                                 46 (17.7)        36 (19.5)         6 (13.3)    4 (13.4)    
   T3                                 168 (64.6)       112 (60.5)        37 (82.3)   19 (63.3)   
   T4                                 21 (8.1)         13 (7.0)          2 (4.4)     6 (20.0)    
  N stage                                                                                        0.698
   N0                                 148 (55.8)       104 (56.3)        23 (51.1)   16 (53.3)   
   N1                                 67 (25.3)        50 (27.0)         9 (20.0)    8 (26.7)    
   N2                                 40 (15.1)        25 (13.5)         10 (22.2)   5 (16.7)    
   N3                                 10 (3.8)         6 (3.2)           3 (6.7)     1 (3.3)     
  TNM stage                                                                                      0.048[\*](#tfn_001){ref-type="table-fn"}
   I                                  24 (9.2)         23 (12.4)         0           1 (3.3)     
   II                                 127 (48.8)       91 (49.2)         23 (51.1)   13 (43.3)   
   III                                109 (41.9)       71 (38.4)         22 (48.9)   16 (53.4)   
  Smoking                                                                                        0.495
   Never                              100 (38.5)       75 (40.5)         14 (31.1)   11 (36.7)   
   Ever                               160 (61.5)       110 (59.5)        31 (68.9)   19 (63.3)   
  Alcohol consumption                                                                            0.071
   Never                              170 (65.4)       128 (69.2)        23 (51.1)   19 (63.3)   
   Ever                               90 (34.6)        57 (30.8)         22 (48.9)   11 (36.7)   
  mGPS                                                                                           \< 0.001[\*](#tfn_001){ref-type="table-fn"}
   0                                  213 (81.9)       185 (100.0)       28 (62.2)   0           
   1                                  42 (16.2)        0                 13 (28.9)   29 (96.7)   
   2                                  5 (1.9)          0                 4 (8.9)     1 (3.3)     

FC, fibrinogen and C-reactive protein; ESCC, esophageal squamous cell carcinoma; TNM, tumor-node-metastasis; mGPS, modified Glasgow prognostic score.

*P* \< 0.05.

Correlation between preoperative FC score and clinicopathologic parameters {#s2_2}
--------------------------------------------------------------------------

Among the 260 patients, 185 (71.2 %) had an FC score of 0 and 75 (28.8%) had an FC score of 1 or 2 (Table [1](#T1){ref-type="table"}). The results demonstrated that preoperative FC score was significantly correlated with degree of differentiation, depth of invasion, tumor-node-metastasis (TNM) stage and mGPS. Whereas no significant differences in age, gender, tumor length, tumor location, lymph node status or smoking were identified between groups (Table [1](#T1){ref-type="table"}). Notably, an mGPS of 1 or 2 was significantly observed more frequently among patients with high preoperative FC score (Table [1](#T1){ref-type="table"}).

Prognostic value of preoperative FC score in predicting long-term survival for ESCC {#s2_3}
-----------------------------------------------------------------------------------

The median follow-up time was 46.5 months. There were one hundred and forty-one patients died during the follow-up period, with an estimated median DFS and OS of 35.5 months (95%CI, 19.0-52.0 months) and 56.3 months (95%CI, 38.1-74.5 months), respectively.

A Cox univariate model for DFS showed that high preoperative FC score was significantly associated with unfavorable DFS (HR, 1.650; 95%CI, 1.181-2.303; *P*=0.003; Figure [1A](#F1){ref-type="fig"}). Gender (Male/Female), tumor length (\<5/≥5 cm), depth of invasion (T1-2/T3-4), lymph node involvement (Negative/Positive), TNM stage (I-II/III), smoking (Never/Ever) and alcohol consumption (Never/Ever) were other significant prognostic variables identified by univariate analysis (*P*\<0.05). On multivariate analysis, TNM stage (HR, 2.209; 95% CI, 1.577-3.095; *P*\<0.001), smoking (HR, 1.755; 95% CI, 1.047-2.942; *P*=0.033) and preoperative FC score (HR, 1.468; 95% CI, 1.043-2.067; *P*=0.028) were suggested to be independent prognostic factors for DFS (Table [2](#T2){ref-type="table"}).

###### Univariate and multivariate analysis of DFS in 260 ESCC patients

  Variables                Univariate   Multivariate                                                                  
  ------------------------ ------------ -------------- --------------------------------------------- ------------- -- ---------------------------------------------
  Age (years)                                                                                                         
   ≥ 60                    1                           0.940                                                          NI
   \< 60                   1.012        0.736-1.393                                                                   
  Gender                                                                                                              
   Male                    1                           0.044[\*](#tfn_002){ref-type="table-fn"}      1                0.554
   Female                  0.672        0.457-0.989    1.182                                         0.679-2.056      
  Tumor location                                                                                                      
   Lower                   1                           0.894                                                          NI
   Middle                  0.929        0.654-1.318                                                                   
   Upper                   1.019        0.541-1.922                                                                   
  Tumor length (cm)                                                                                                   
   \< 5                    1                           0.019\*                                       1                0.203
   ≥ 5                     1.464        1.066-2.012    1.179                                         0.848-1.640      
  Differentiation                                                                                                     
   Well/Moderate           1                           0.788                                                          NI
   Poor/Undifferentiated   1.053        0.724-1.530                                                                   
  Depth of invasion                                                                                                   
   T1/T2                   1                           \< 0.001\*                                                     NI
   T3/T4                   2.147        1.438-3.205                                                                   
  Lymph node involvement                                                                                              
   Negative                1                           \< 0.001\*                                                     NI
   Positive                2.854        2.056-3.962                                                                   
  TNM stage                                                                                                           
   I/II                    1                           \< 0.001[\*](#tfn_002){ref-type="table-fn"}   1                \< 0.001[\*](#tfn_002){ref-type="table-fn"}
   III                     2.439        1.766-3.368    2.209                                         1.577-3.095      
  Smoking                                                                                                             
   Never                   1                           0.002[\*](#tfn_002){ref-type="table-fn"}      1                0.033[\*](#tfn_002){ref-type="table-fn"}
   Ever                    1.734        1.229-2.448    1.755                                         1.047-2.942      
  Alcohol consumption                                                                                                 
   Never                   1                           0.019\*                                       1                0.758
   Ever                    1.476        1.065-2.044    0.941                                         0.638-1.387      
  mGPS                                                                                                                
   0                       1                           0.123                                                          NI
   1/2                     1.360        0.920-2.008                                                                   
  FC score                                                                                                            
   0                       1                           0.003[\*](#tfn_002){ref-type="table-fn"}      1                0.028[\*](#tfn_002){ref-type="table-fn"}
   1/2                     1.650        1.181-2.303    1.468                                         1.043-2.067      

DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; NI, not included.

*P* \< 0.05.

![Kaplan-Meier survival curves of\
**A.**, disease-free survival (DFS) and **B.**, overall survival (OS) stratified by preoperative fibrinogen and C-reactive protein (FC) score in 260 esophageal squamous cell carcinoma (ESCC) patients (with log-rank test).](oncotarget-07-61533-g001){#F1}

Univariate analysis of OS indicated that patients with high preoperative FC score tended to have impaired OS (HR, 1.879; 95% CI, 1.333-2.648; *P*\<0.001; Figure [1B](#F1){ref-type="fig"}). Besides, other parameters including depth of invasion, lymph node involvement, TNM stage, smoking, alcohol consumption and mGPS could also significantly predict OS. Multivariate analysis was then performed using a Cox proportional hazards model. After adjusting for other confounding variables, we found that high FC score could also serve as an independent predictor for OS (HR, 2.070; 95% CI, 1.266-3.385; *P*=0.004). As expected, TNM stage was another significant predictor for OS. Compared with TNM stage I-II patients, those with TNM stage III had poorer OS (HR, 2.150; 95% CI, 1.523-3.034; *P*\<0.001) (Table [3](#T3){ref-type="table"}).

###### Univariate and multivariate analysis of OS in 260 ESCC patients

  Variables                Univariate   Multivariate                                                                  
  ------------------------ ------------ -------------- --------------------------------------------- ------------- -- ---------------------------------------------
  Age (years)                                                                                                         
   ≥ 60                    1                           0.450                                                          NI
   \< 60                   1.136        0.816-1.582                                                                   
  Gender                                                                                                              
   Male                    1                           0.060                                                          NI
   Female                  0.681        0.457-1.016                                                                   
  Tumor location                                                                                                      
   Lower                   1                           0.876                                                          NI
   Middle                  0.933        0.646-1.368                                                                   
   Upper                   1.069        0.550-2.076                                                                   
  Tumor length (cm)                                                                                                   
   \< 5                    1                           0.081                                                          NI
   ≥ 5                     1.344        0.965-1.873                                                                   
  Differentiation                                                                                                     
   Well/Moderate           1                           0.791                                                          NI
   Poor/Undifferentiated   1.054        0.716-1.550                                                                   
  Depth of invasion                                                                                                   
   T1/T2                   1                           \< 0.001[\*](#tfn_003){ref-type="table-fn"}                    NI
   T3/T4                   2.254        1.471-3.455                                                                   
  Lymph node involvement                                                                                              
   Negative                1                           \< 0.001[\*](#tfn_003){ref-type="table-fn"}                    NI
   Positive                2.799        1.989-3.938                                                                   
  TNM stage                                                                                                           
   I/II                    1                           \< 0.001[\*](#tfn_003){ref-type="table-fn"}   1                \< 0.001[\*](#tfn_003){ref-type="table-fn"}
   III                     2.319        1.658-3.242    2.150                                         1.523-3.034      
  Smoking                                                                                                             
   Never                   1                           0.004[\*](#tfn_003){ref-type="table-fn"}      1                0.084
   Ever                    1.683        1.178-2.407    1.445                                         0.952-2.192      
  Alcohol consumption                                                                                                 
   Never                   1                           0.007[\*](#tfn_003){ref-type="table-fn"}      1                0.818
   Ever                    1.597        1.139-2.240    1.049                                         0.698-1.577      
  mGPS                                                                                                                
   0                       1                           0.042[\*](#tfn_003){ref-type="table-fn"}      1                0.341
   1/2                     1.514        1.016-2.257    0.760                                         0.432-1.337      
  FC score                                                                                                            
   0                       1                           \< 0.001[\*](#tfn_003){ref-type="table-fn"}   1                0.004\*
   1/2                     1.879        1.333-2.648    2.070                                         1.266-3.385      

OS, overall survival.

*P* \< 0.05.

Furthermore, subgroup analysis based on different T stages and lymph node status indicated that high preoperative FC score was significantly correlated with unfavorable DFS (Figure [2A](#F2){ref-type="fig"}, [3A, 3C](#F3){ref-type="fig"}; *P*\<0.05) and OS (Figure [2B, 2D](#F2){ref-type="fig"}, [3B, 3D](#F3){ref-type="fig"}; *P*\<0.05) in certain patients, but not DFS in T3-4 stage ESCC patients (Figure [2C](#F2){ref-type="fig"}; *P*\>0.05).

![Kaplan-Meier survival curves of\
**A.**, DFS and **B.**, OS stratified by preoperative FC score in T1-2 stage ESCC patients (n=71); **C.**, DFS and **D.**, OS stratified by preoperative FC score in T3-4 stage ESCC patients (n=189) (with log-rank test).](oncotarget-07-61533-g002){#F2}

![Kaplan-Meier survival curves of\
**A.**, DFS and **B.**, OS stratified by preoperative FC score in ESCC patients without lymph node involvement (n=143); **C.**, DFS and **D.**, OS stratified by preoperative FC score in ESCC patients with lymph node involvement (n=117) (with log-rank test).](oncotarget-07-61533-g003){#F3}

DISCUSSION {#s3}
==========

Nowadays, neoadjuvant chemoradiotherapy followed by radical surgery has been recommended as the optimal treatment strategy for locally advanced ESCC. However, to the best of our knowledge, in most less-developed urban and rural areas of China, as well as in low-incoming countries such as African and Central Asia, due to the unreasonable and imbalanced health resources allocation, together with the lack of experienced and professional multidisciplinary treatment team, a vast majority of locally advanced ESCC cases were initially referred to the department of thoracic surgery without preoperative treatment, leaving radical surgery alone or in combination with adjuvant treatment as the "standard care" in such regions.

The present study demonstrated that preoperative FC score was significantly correlated with the clinical stage and postoperative long-term survival, suggesting that those with high preoperative FC scores have more advanced and progressive disease, as well as impaired prognosis. Thus, patients who had high risk of local recurrence or distant metastasis could be identified according to the preoperative FC score, and neoadjuvant induction or further intense adjuvant treatment should be suggested. Additionally, further subgroup analysis revealed that preoperative FC score remained significantly prognostic for both DFS and OS in certain patients, whereas with the exception of DFS in T3-4 stage ESCC patients. In fact, approximately 50% of the two group patients with T3-4 disease experienced postoperative local recurrence or distant metastasis within two years after the surgery. However, the reliable underlying mechanism for elucidating the phenomenon has yet to be investigated. And most of them received salvage treatment, including local radiotherapy and/or systematic chemotherapy thereafter. To the best of our knowledge, this study was the first one reporting the prognostic value of preoperative FC score in ESCC.

mGPS is widely used as a valuable and convenient prognostic indicator in various malignancies, including ESCC \[[@R8], [@R23]--[@R25]\]. However, we failed to identify mGPS as an independent prognostic indicator in the present study. Neither did Arigami et al. found its independent prognostic significance in 238 ESCC patients who underwent esophagectomy with lymphadenectomy \[[@R26]\]. As previous studies have suggested that in operable esophageal cancer patients, systemic inflammation and nutritional deficiencies were insufficient for high-risk stratification \[[@R22], [@R27]--[@R28]\]. Besides, albumin levels were not always decreased in esophageal cancer patients \[[@R22]\]. Therefore, we selected plasma fibrinogen as an alternative.

As an essential hemostatic factor, fibrinogen is synthesized in the liver and secreted into the circulation, and then converted to fibrin in response to infection, tissue injury or inflammation \[[@R29]--[@R32]\]. Few studies examining the clinical significance of plasma fibrinogen in esophageal cancer have been conducted. Results from two previous studies indicated that pretreatment plasma fibrinogen was significantly correlated with tumor progression and metastasis in ESCC patients \[[@R14]\], and it could predict postoperative recurrence for those who received neoadjuvant therapy \[[@R15]\]. In addition, Wang et al. found that hyperfibrinogenemia was a valuable predictor for disease progression in resectable ESCC. However, they failed to determine it as an independent prognostic indicator in multivariate analysis \[[@R16]\]. Moreover, Zhang et al. showed that increased plasma fibrinogen level was significantly associated with elevated risk of ESCC, and preoperative hyperfibrinogenemia was a negative prognostic factor for survival of patients with ESCC \[[@R17]\]. Furthermore, as an systematic inflammation response marker, CPR has also been identified as an independent prognostic indicator for various malignancies \[[@R20]--[@R21]\]. Therefore, in combination with fibrinogen, CRP might show more potent prognostic value among ESCC patients.

Notably, only five patients were allocated an mGPS of 2 in the present study, leading to an inferior risk classification. As prior studies indicated that systemic inflammation and nutritional deficiencies might not be serious in early or locally advanced esophageal caner patients. Therefore, those with elevated CRP and decreased albumin levels could not be commonly observed \[[@R22], [@R27]--[@R28]\]. Furthermore, the COX multivariate regression analysis identified TNM stage and preoperative FC score as significant prognostic indicators for both DFS and OS, suggesting that preoperative FC score was superior to mGPS in predicting long-term survival in ESCC patient who underwent transthoracic esophagectomy.

Although this study was mainly limited to its retrospective and single-center design, the results showed that preoperative FC score might serve as a new potential marker to predict long-term survival, and facilitate more accurate risk stratification and individualized multidisciplinary treatment for ESCC patients. However, further prospective and large cohort studies are needed to validate these findings.

PATIENTS AND METHODS {#s4}
====================

Patients {#s4_1}
--------

A consecutive cohort of 260 patients with histopathologically diagnosed ESCC who underwent curative transthoracic esophagectomy at the Department of Thoracic Surgery, Anhui Cancer Hospital and Anhui Provincial Hospital between January 2007 and December 2011. Patients who received preoperative chemotherapy and/or radiotherapy, patients who had concurrent disease that would affect the hemostatic system (e.g. liver disease and blood coagulation disorders), those who received anticoagulants, corticosteroids, estrogen, or aspirin treatment within 1 month before the surgery, patients who had systemic diseases such as systemic lupus erythematosus (SLE), acquired immunodeficiency syndrome (AIDS), nephrotic syndrome (NS) and rheumatoid arthritis (RA), and those diagnosed with chronic inflammatory diseases or infections, as well as \>= grade 2 hypoalbuminemia were also excluded. This study was approved by the independent ethics committees at our hospital and was performed in accordance with the ethical standards of the World Medical Association Declaration of Helsinki.

Treatment and follow up {#s4_2}
-----------------------

All patients underwent a left or right transthoracic esophagectomy with curative intent, and at least a two-field regional lymphadenectomy, including standard, extended, or total dissection of the cervical, thoracic and abdominal lymph nodes, was performed. None of the included patients received adjuvant treatment. Postoperative followed-up including upper gastrointestinal endoscopy, tumor marker and computed tomography were regularly evaluated every 6 months for 5 years after surgery. Disease free survival (DFS) was defined as the date of surgery to local recurrence/distant metastasis or to the last date of follow-up, OS was the time interval from the date of diagnosis to death from any cause or to the most recent follow-up.

Clinical and laboratory parameters {#s4_3}
----------------------------------

Patients\' clinicopathologic variables, preoperative plasma fibrinogen, serum CRP and albumin levels, as well as postoperative survival were retrospectively reviewed and collected from the medical records. The AJCC/UICC TNM staging system (the 7th edition) was utilized to classify the tumor stage. The tumor length was defined as the long diameter measured with the general post-operative pathological specimens. The degree of differentiation was categorized into poorly/not differentiated, moderately differentiated and well differentiated. And the tumor locations were classified into upper esophagus, middle esophagus and lower esophagus.

Preoperative plasma fibrinogen, serum CRP and albumin levels were examined in samples obtained within 7 days prior to surgery. Plasma fibrinogen concentrations were determined using an automatic coagulation analyzer (Beckman Coulter DC800, USA). Serum CRP and albumin levels were tested by an automatic biochemical analyzer (Roche 501, Japan).

Fibrinogen and C-reactive protein score (FC score) and modified glasgow prognostic score (mGPS) {#s4_4}
-----------------------------------------------------------------------------------------------

The optimal cut-off value for fibrinogen and CRP was defined as 4.0 g/dL and 10.0 mg/L according to previous reports \[[@R7]--[@R8], [@R18]--[@R20]\]. Patients with elevated fibrinogen (≥ 4.0g/dL) and CRP (≥ 10.0 mg/L) levels were assigned an FC score of 2, those with only one of these two abnormalities were allocated a score of 1, and those with neither of the two abnormalities were assigned a score of 0.

As previously described, patients with decreased CRP (\< 10.0 mg/L) levels were allocated an mGPS of 0, those with both elevated CRP (\> 10.0 mg/L) and albumin (\> 35.0 g/L) were assigned a score of 1, while patients with both elevated CRP and decreased albumin (\< 35.0 g/L) were allocated a score of 2.

Statistical analysis {#s4_5}
--------------------

Differences between categories were identified using the Chi-square test. Survival curves were estimated using the Kaplan-Meier method, and differences were compared with log-rank test. Univariate and multivariate analysis were performed using Cox proportional hazards regression models and hazard ratios (HRs) for variables respecting to DFS and OS were calculated. HRs with 95% confidence intervals (CIs) and two-sided *P* value were reported. All statistical analyses were performed with SPSS 17.0 (SPSS Inc., Chicago, IL, USA). And a two-sided *P* value of less than 0.05 was considered to be statistically significant.
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